{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:55:12Z","timestamp":1780995312395,"version":"3.54.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>CC chemokine receptor 4 (CCR4), the receptor for CCL22 and CCL17, is expressed on the surface of effector Tregs that have the highest suppressive effects on antitumor immune response. CCR4 is also widely expressed on the surface of tumor cells from patients with adult T-cell leukemia\/lymphoma (ATL), peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). Mogamulizumab is a humanized, IgG1 kappa monoclonal antibody that is directed against CCR4. By reducing the number of CCR4-positive Tregs and tumor cells, the mogamulizumab can reduce tumor burden and boost antitumor immunity to achieve antitumor effects.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We examined the PubMed and <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link> until 1 February 2020. Considering variability in different studies, we selected the adverse events (AEs), overall survival (OS), progression-free survival (PFS), objective responses rate (ORR) and Hazard Ratio (HR) for PFS to evaluate the safety and efficacy profile of mogamulizumab.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>When patients were treated with mogamulizumab monotherapy, the most common all-grade AEs were lymphopenia, infusion reaction, fever, rash and chills while the most common grade\u2009\u2265\u20093 AEs were lymphopenia, neutropenia and rash. When patients were treated with combined therapy of mogamulizumab and other drugs, the most common all-grade AEs were neutropenia, anaemia, lymphopenia and gastrointestinal disorder, while the most common grade\u2009\u2265\u20093 AEs was lymphopenia. For patients treated with mogamulizumab monotherapy, the pooled ORR and mean PFS were 0.430 (95% CI: 0.393\u20130.469) and 1.060\u2009months (95% CI: 1.043\u20131.077), respectively. For patients treated with combined therapy of mogamulizumab and other drugs, the pooled ORR was 0.203 (95% CI: 0.022\u20130.746) while the pooled PFS and OS were 2.093\u2009months (95% CI: 1.602\u20132.584) and 6.591\u2009months (95% CI: 6.014\u20137.167), respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Based on present evidence, we believed that mogamulizumab had clinically meaningful antitumor activity with acceptable toxicity which is a novel therapy in treating patients with cancers.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08363-w","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T20:03:20Z","timestamp":1622059400000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies"],"prefix":"10.1186","volume":"21","author":[{"given":"Ting","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunuo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoning","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9148-5001","authenticated-orcid":false,"given":"Xuelei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,26]]},"reference":[{"key":"8363_CR1","doi-asserted-by":"crossref","unstructured":"Yoshie O, Matsushima KJII. CCR4 and its ligands: from bench to bedside.\u00a0Int immun.\u00a02015;27(1):11\u201320.","DOI":"10.1093\/intimm\/dxu079"},{"key":"8363_CR2","doi-asserted-by":"crossref","unstructured":"Wu XS, Lonsdorf AS, STJJoID H. Cutaneous T-Cell Lymphoma: Roles for Chemokines and Chemokine Receptors. J Invest Dermatol\u00a02009;129(5):1115\u20139.","DOI":"10.1038\/jid.2009.45"},{"key":"8363_CR3","doi-asserted-by":"crossref","unstructured":"Sokolowska-Wojdylo M, Wenzel J, Gaffal E, Lenz J, TTJBJo D. Circulating clonal CLA+ and CD4+ T cells in S\u00e9zary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7. Br J Dermatol\u00a02005;152(2):258\u201364.","DOI":"10.1111\/j.1365-2133.2004.06325.x"},{"key":"8363_CR4","volume-title":"Oncology UJJJoC: Current status of immunotherapy","author":"S Susumu","year":"2016","unstructured":"Susumu, Suzuki, Takashi, Ishida, Kazuhiro, Yoshikawa, Ryuzo, Oncology UJJJoC: Current status of immunotherapy. 2016."},{"key":"8363_CR5","doi-asserted-by":"crossref","unstructured":"Ferenczi K, Fuhlbrigge RC, Pinkus J, Pinkus GS, Kupper TS. Increased CCR4 expression in cutaneous T cell lymphoma. J invest Dermatol\u00a02002;119(6):1405\u201310.","DOI":"10.1046\/j.1523-1747.2002.19610.x"},{"key":"8363_CR6","doi-asserted-by":"crossref","unstructured":"Sugaya M, Morimura S, Suga H, Kawaguchi M, Miyagaki T, Ohmatsu H, et al. CCR4 is expressed on infiltrating cells in lesional skin of early mycosis fungoides and atopic dermatitis. J Dermatol 2015;42(6):613\u20135.","DOI":"10.1111\/1346-8138.12852"},{"issue":"1","key":"8363_CR7","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1182\/asheducation-2015.1.529","volume":"2015","author":"M Duvic","year":"2015","unstructured":"Duvic M. Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and S\u00e9zary syndrome. Hematol Am Soc Hematol Educ Program. 2015;2015(1):529\u201344. https:\/\/doi.org\/10.1182\/asheducation-2015.1.529.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"3","key":"8363_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1177\/2040620716636541","volume":"7","author":"M Duvic","year":"2016","unstructured":"Duvic M, Evans M, Wang C. Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. Ther Adv Hematol. 2016;7(3):171\u20134. https:\/\/doi.org\/10.1177\/2040620716636541.","journal-title":"Ther Adv Hematol"},{"key":"8363_CR9","doi-asserted-by":"crossref","unstructured":"Ishida. Research TJCC: CXC Chemokine Receptor 3 and CC Chemokine Receptor 4 Expression in T-Cell and NK-Cell Lymphomas with Special Reference to Clinicopathological Significance for Peripheral T-Cell Lymphoma, Unspecified. Clin Cancer Res. 2004;10(16):5494\u2013500.","DOI":"10.1158\/1078-0432.CCR-04-0371"},{"issue":"1","key":"8363_CR10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/jcph.1548","volume":"60","author":"M Mukai","year":"2020","unstructured":"Mukai M, Mould D, Maeda H, Narushima K, Greene D. Exposure-response analysis for Mogamulizumab in adults with cutaneous T-cell lymphoma. J Clin Pharmacol. 2020;60(1):50\u20137. https:\/\/doi.org\/10.1002\/jcph.1548.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"8363_CR11","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/ejh.12863","volume":"98","author":"M Sekine","year":"2017","unstructured":"Sekine M, Kubuki Y, Kameda T, Takeuchi M, Toyama T, Kawano N, et al. Effects of mogamulizumab in adult T-cell leukemia\/lymphoma in clinical practice. Eur J Haematol. 2017;98(5):501\u20137. https:\/\/doi.org\/10.1111\/ejh.12863.","journal-title":"Eur J Haematol"},{"issue":"24","key":"8363_CR12","doi-asserted-by":"publisher","first-page":"7275","DOI":"10.1158\/1078-0432.CCR-19-2030","volume":"25","author":"YL Kasamon","year":"2019","unstructured":"Kasamon YL, Chen H, de Claro RA, Nie L, Ye J, Blumenthal GM, et al. FDA approval summary: Mogamulizumab-kpkc for mycosis Fungoides and S\u00e9zary syndrome. Clin Cancer Res. 2019;25(24):7275\u201380. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2030.","journal-title":"Clin Cancer Res"},{"key":"8363_CR13","doi-asserted-by":"crossref","unstructured":"Wan X, Wang W, Liu J, TJBmrm T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol\u00a02014;14:135.","DOI":"10.1186\/1471-2288-14-135"},{"issue":"12","key":"8363_CR14","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1182\/blood-2014-09-600924","volume":"125","author":"M Duvic","year":"2015","unstructured":"Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, et al. Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015;125(12):1883\u20139. https:\/\/doi.org\/10.1182\/blood-2014-09-600924.","journal-title":"Blood"},{"issue":"8","key":"8363_CR15","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","volume":"30","author":"T Ishida","year":"2012","unstructured":"Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30(8):837\u201342. https:\/\/doi.org\/10.1200\/JCO.2011.37.3472.","journal-title":"J Clin Oncol"},{"issue":"4","key":"8363_CR16","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s12185-017-2270-9","volume":"106","author":"K Ishitsuka","year":"2017","unstructured":"Ishitsuka K, Yurimoto S, Kawamura K, Tsuji Y, Iwabuchi M, Takahashi T, et al. Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance. Int J Hematol. 2017;106(4):522\u201332. https:\/\/doi.org\/10.1007\/s12185-017-2270-9.","journal-title":"Int J Hematol"},{"issue":"9","key":"8363_CR17","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","volume":"19","author":"YH Kim","year":"2018","unstructured":"Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192\u2013204. https:\/\/doi.org\/10.1016\/S1470-2045(18)30379-6.","journal-title":"Lancet Oncol"},{"issue":"19","key":"8363_CR18","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1158\/1078-0432.CCR-15-0357","volume":"21","author":"K Kurose","year":"2015","unstructured":"Kurose K, Ohue Y, Wada H, Iida S, Ishida T, Kojima T, et al. Phase Ia study of FoxP3+ CD4 Treg depletion by infusion of a humanized anti-CCR4 antibody, KW-0761, in Cancer patients. Clin Cancer Res. 2015;21(19):4327\u201336. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0357.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"8363_CR19","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1007\/s12185-018-2509-0","volume":"108","author":"J Nakashima","year":"2018","unstructured":"Nakashima J, Imaizumi Y, Taniguchi H, Ando K, Iwanaga M, Itonaga H, et al. Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma. Int J Hematol. 2018;108(5):516\u201323. https:\/\/doi.org\/10.1007\/s12185-018-2509-0.","journal-title":"Int J Hematol"},{"issue":"11","key":"8363_CR20","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","volume":"32","author":"M Ogura","year":"2014","unstructured":"Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32(11):1157\u201363. https:\/\/doi.org\/10.1200\/JCO.2013.52.0924.","journal-title":"J Clin Oncol"},{"issue":"5","key":"8363_CR21","doi-asserted-by":"publisher","first-page":"993","DOI":"10.3324\/haematol.2018.205096","volume":"104","author":"AA Phillips","year":"2019","unstructured":"Phillips AA, Fields PA, Hermine O, Ramos JC, Beltran BE, Pereira J, et al. Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed\/refractory adult T-cell leukemia\/lymphoma. Haematologica. 2019;104(5):993\u20131003. https:\/\/doi.org\/10.3324\/haematol.2018.205096.","journal-title":"Haematologica"},{"issue":"9","key":"8363_CR22","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1200\/JCO.2009.25.3575","volume":"28","author":"K Yamamoto","year":"2010","unstructured":"Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28(9):1591\u20138. https:\/\/doi.org\/10.1200\/JCO.2009.25.3575.","journal-title":"J Clin Oncol"},{"issue":"10","key":"8363_CR23","doi-asserted-by":"publisher","first-page":"e407","DOI":"10.3324\/haematol.2016.146977","volume":"101","author":"PL Zinzani","year":"2016","unstructured":"Zinzani PL, Karlin L, Radford J, Caballero D, Fields P, Chamuleau MED, et al. European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed\/refractory peripheral T-cell lymphoma. Haematologica. 2016;101(10):e407\u201310. https:\/\/doi.org\/10.3324\/haematol.2016.146977.","journal-title":"Haematologica"},{"issue":"1","key":"8363_CR24","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1186\/s40425-019-0815-6","volume":"7","author":"EEW Cohen","year":"2019","unstructured":"Cohen EEW, Pishvaian MJ, Shepard DR, Wang D, Weiss J, Johnson ML, et al. A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors. J Immunother Cancer. 2019;7(1):342. https:\/\/doi.org\/10.1186\/s40425-019-0815-6.","journal-title":"J Immunother Cancer"},{"issue":"22","key":"8363_CR25","doi-asserted-by":"publisher","first-page":"6614","DOI":"10.1158\/1078-0432.CCR-19-1090","volume":"25","author":"T Doi","year":"2019","unstructured":"Doi T, Muro K, Ishii H, Kato T, Tsushima T, Takenoyama M, et al. A phase I study of the anti-CC chemokine receptor 4 antibody, Mogamulizumab, in combination with Nivolumab in patients with advanced or metastatic solid tumors. Clin Cancer Res. 2019;25(22):6614\u201322. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1090.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"8363_CR26","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/bjh.13338","volume":"169","author":"T Ishida","year":"2015","unstructured":"Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol. 2015;169(5):672\u201382. https:\/\/doi.org\/10.1111\/bjh.13338.","journal-title":"Br J Haematol"},{"key":"8363_CR27","unstructured":"Study of mogamulizumab + docetaxel in subjects with non-small cell lung cancer. Available from: http:\/\/ clinicaltrialsgov\/show\/NCT02358473."},{"key":"8363_CR28","doi-asserted-by":"crossref","unstructured":"Niwa R, Sakurada M, Kobayashi Y, Uehara A, Matsushima K, Ueda R, et al. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res\u00a02005;11(6):2327.","DOI":"10.1158\/1078-0432.CCR-04-2263"},{"issue":"5","key":"8363_CR29","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-09-2697","volume":"16","author":"T Ishii","year":"2010","unstructured":"Ishii T, Ishida T, Utsunomiya A, Inagaki A, Yano H, Komatsu H, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia\/lymphoma. Clin Cancer Res. 2010;16(5):1520\u201331. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-2697.","journal-title":"Clin Cancer Res"},{"key":"8363_CR30","doi-asserted-by":"crossref","unstructured":"Ni X, Langridge T, Duvic MJO. Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab. Oncoimmunology\u00a02015;4(7):e1011524.","DOI":"10.1080\/2162402X.2015.1011524"},{"key":"8363_CR31","doi-asserted-by":"crossref","unstructured":"Remer M, Al-Shamkhani A, Glennie M, Johnson PJI. Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas. Immuno 2014;6(11):1187\u2013206.","DOI":"10.2217\/imt.14.94"},{"key":"8363_CR32","doi-asserted-by":"crossref","unstructured":"Campbell JJ. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature.\u00a01999;400(6746):776\u201380.","DOI":"10.1038\/23495"},{"key":"8363_CR33","doi-asserted-by":"crossref","unstructured":"Girardi M, Heald PW, LDJNEJoM W. The Pathogenesis of Mycosis Fungoides. New Eng J\u00a0 Med. 2004;350(19):1978\u201388.","DOI":"10.1056\/NEJMra032810"},{"key":"8363_CR34","doi-asserted-by":"crossref","unstructured":"Kinnunen T, Chamberlain N, Morbach H, Choi J, Kim S, Craft J, et al. Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells. Blood;\u00a02013;121(9):1595\u2013603.","DOI":"10.1182\/blood-2012-09-457465"},{"key":"8363_CR35","doi-asserted-by":"crossref","unstructured":"Suzuki Y, Saito M, Ishii T, Urakawa I, Matsumoto A, Masaki A, et al. Mogamulizumab Treatment Elicits Autoantibodies Attacking the Skin in Patients with Adult T-Cell Leukemia-Lymphoma. Clin Cancer Res\u00a02019;25(14):4388\u201399.","DOI":"10.1158\/1078-0432.CCR-18-2575"},{"key":"8363_CR36","doi-asserted-by":"crossref","unstructured":"Saito M, Ishii T, Urakawa I, Matsumoto A, Ishida TJBA. Robust CD8+ T-cell proliferation and diversification after mogamulizumab in patients with adult T-cell leukemia-lymphoma. Blood adv;\u00a02020;4(10):2180\u201391.","DOI":"10.1182\/bloodadvances.2020001641"},{"key":"8363_CR37","doi-asserted-by":"crossref","unstructured":"Ishida T, Ito A, Sato F, Kusumoto S, Iida S, Inagaki H, et al. Ueda RJCe: Stevens\u2013Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia\/lymphoma. Cancer Sci;\u00a02013;104(5):647\u201350.","DOI":"10.1111\/cas.12116"},{"key":"8363_CR38","doi-asserted-by":"crossref","unstructured":"Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, et al. Regulatory T Cells Recruited through CCL22\/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome. Cancer Res. 2009;69(5):2000\u20139.","DOI":"10.1158\/0008-5472.CAN-08-2360"},{"key":"8363_CR39","doi-asserted-by":"crossref","unstructured":"Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem\u00a02003;278(5):3466\u201373.","DOI":"10.1074\/jbc.M210665200"},{"key":"8363_CR40","doi-asserted-by":"crossref","unstructured":"Ishida T. Science RUJC: CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci 2006;97(11):1139\u201346.","DOI":"10.1111\/j.1349-7006.2006.00307.x"},{"key":"8363_CR41","doi-asserted-by":"crossref","unstructured":"Segal NH, He AR, Doi T, Levy R, Bhatia S, Pishvaian MJ, et al. Huang BJCCR: Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB\/CD137 Agonist, in Patients with Advanced Cancer. Clin Cancer Res\u00a02018;1078\u20130432:CCR-1017-1922.","DOI":"10.1158\/1078-0432.CCR-17-1922"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08363-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08363-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08363-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T20:09:50Z","timestamp":1622059790000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08363-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,26]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8363"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08363-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,26]]},"assertion":[{"value":"28 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research is a pooled meta-analysis of published data and does not include any studies with human participants or animals performed by any of the authors. Hence, the ethics approval and consent are not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"618"}}